The prostacyclin analog, treprostinil sodium, provides symptom relief in severe Buerger's disease--a case report and review of literature.

Abstract

Buerger's disease (thromboangiitis obliterans or TAO) is a clinical syndrome characterized by the development of segmental thrombotic occlusions of the medium and small arteries. The primary treatment for Buerger's disease is cessation of cigarette smoking. In patients whose disease progresses despite smoking cessation, therapeutic options are limited. Revascularization is rarely indicated and usually not successful because of the diffuse and distal distribution of the disease. Prostacyclin, or PGI2, and its analogs have been proposed as pharmacotherapy for Buerger's disease and studied in Europe. The authors review the prostacyclin literature in the treatment of Buerger's disease and present a case report of a patient with progressive Buerger's disease and the use of treprostinil sodium (Remodulin). This case report experience suggests hat subcutaneous treprostinil therapy could be clinically useful in Buerger's disease that does not improve with smoking cessation, particularly in the presence of critical limb ischemia where other therapeutic options have failed.

• Authors: Bernardo Fernandez, Deborah Strootman
• Journal: Angiology (Angiology) 2006 Jan-Feb Vol. 57 Issue 1 Pg. 99-102 ISSN: 0003-3197 [Print] United States
• PMID: 16444463 (Publication Type: Case Reports, Journal Article)

Chemical References

• Epoprostenol
• treprostinil

Topics

• Adult
• Angiography
• Disease Progression
• Epoprostenol (administration & dosage, analogs & derivatives, therapeutic use)
• Follow-Up Studies
• Humans
• Injections, Subcutaneous
• Male
• Severity of Illness Index
• Thromboangiitis Obliterans (diagnostic imaging, drug therapy)